Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial towards patient enrolment, with key study partners now engaged and the investigational product ready for distribution. This impending trial takes the company a step closer to developing a more precise cancer imaging offering that fills a key gap in clinical
Read MoreAcrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market after expanding its licensing agreement with long-term partner Gedeon Richter Plc. The move could deliver Acrux up to AUD 5.4 million in milestone payments over a set period. The amended agreement comes at a critical time for Australian women, with
Read More
Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical trial seeking a treatment for depression which has failed to meet its primary endpoint. In our fast-paced world, balancing a busy work schedule with life’s inevitable ups and downs can be challenging. Drugs for cognitive
Read More
With mixed quarter results for the June quarter, Holista Colltech (ASX: HCT) – a research-driven biotech company, is trying to stay afloat amidst challenges. Dedicated to developing and commercialising innovative food products, the Perth based company has seen a decline of 3.7% in overall sales receipts. With a focus on natural ingredients the company has
Read More
A new drug seeking to treat irritability associated with Autism Spectrum Disorder (ASD) could soon be making its way to clinical trials in healthy volunteers after Zelira Therapeutics (ASX: ZLD) concluded a positive round of discussions with the United States Food and Drug Administration (FDA) on a study design. The proposed clinical trials are for
Read More
Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility Empax Centre. The centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics. The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen
Read More